[1] Ferlay J, Ervik M, Bray F, et al.Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer[EB/OL].[2021-06-15]. https://giarc.fr/today. [2] Zhang SL, Ai DD, Zhang R, et al.Study on drug characteristics of NCCN and CSCO clinical practice guidelines for high-prevalence tumors in China[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(20): 2447-2452. [3] Si L, Xu L, Cheng M, et al.Using strategic price negotiations to contain costs and expand access to medicines in China[J]. BMJ Global Health, 2020, 5(1): e002256. [4] National Health Commission of the People's Republic of China.Guidelines for the clinical application of innovative anticancer drugs[EB/OL]. (2020-12-30) [2021-06-15]. http://www.nhc.gov.cn/yzygj/s7659/202012/6c00e8559ee54cd29585c7f39e8a23c4.shtml. [5] Li HY, Yang CP, Jin HT.Research progress in target related toxicity of anti-tumor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(3): 152-157. [6] Guan XD, Shi LW.Study on evaluation method for the accessibility of essential medicine in China based on WHO/HAI standardized approach[J]. China Pharmacy(中国药房), 2013 (24): 2212-2215. [7] Zhou T, Li HC, Zhang JY, et al.The application and its enlightenment of pharmacoeconomic evidence in australian pharmaceutical benefits scheme access[J]. Chinese Health Economics(中国卫生经济), 2018, 37(5): 54-56. [8] Anum S, Sadia I, Muhammad RS.Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan[J]. BMJ Open, 2018, 8(6): e019015. [9] Changzhou people's govenment. Changzhou municipal human resources and social security bureau. Notice on the adjustment of minimum wage standard in Changzhou.[EB/OL].(2018-07-20)[2020-01-21].http://www.changzhou.gov.cn/gi_news/419153207791914. [10] Fang X, Tian MY, Zhang YX, et al.Drugs administration and individual affordability under different medical insurance entry 11 price: example of anti-tumor targeted medicare drugs[J]. Chinese 12 Journal of Health Policy(中国卫生政策研究), 2016, 9(11): 40-44. [11] Zhang L, Zhou QY, Zhang XM, et al.Investigation and study on the accessibility of antibiotics in essential medicine list in medical institutions of Nanjing area[J]. China Pharmacy(中国药房), 2020, 31(11): 1281-1287. [12] Sun KX, Zheng RS, Zhang SW, et al.Report of cancer incidence and mortality in different areas of China, 2015[J]. China Cancer(中国肿瘤), 2019, 28(1): 1-11. [13] Tang YY, Chen J, Li X.Utilization analysis of the original and generic drugs for hypertension and diabetes in a tertiary public hospital in Jiangsu Province[J]. China Pharmacy(中国药房), 2019, 30(21): 2890-2893. [14] Wan B, Hu DY, Zhang W, et al.Study on the operation performance of medical insurance funds in Jiangsu under the medical and drug insurance policy reform[J]. Chinese Health Economics(中国卫生经济), 2020, 39(4): 36-39. [15] Fan CJ, Wang LN, Yang YM.Study on the effect of implementing the drug zero mark-up policy in public hospitals in China[J]. Health Economics Research(卫生经济研究), 2019, 36(2): 53-56. [16] Chen LL, Xu W, Shang BB, et al.Research on the availability of national negotiated drugs—an empirical analysis based on the purchasing data of public hospitals in Suzhou[J]. Health Economics Research(卫生经济研究), 2020, 37(12): 17-20. |